Inflammation in cystic fibrosis lung disease: Pathogenesis and therapy

Journal of Cystic Fibrosis

Volumn 14, Issue 4, 2015, Pages 419-430

  Cantin, André M ^a   Hartl, Dominik ^b   Konstan, Michael W ^c   Chmiel, James F ^c  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Anti inflammatory therapies; Bronchiectasis; Cystic fibrosis; Lung inflammation; Mucosal immunity; Neutrophils

Indexed keywords

ANTIINFECTIVE AGENT; CALGRANULIN; CORTICOSTEROID; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GLUTATHIONE; IBUPROFEN; LEUKOCYTE ELASTASE; MUCIN; SERINE PROTEINASE; TRANSCRIPTION FACTOR; ANTIINFLAMMATORY AGENT;

ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL THERAPY; BACTERIAL CLEARANCE; BRONCHIECTASIS; CORTICOSTEROID THERAPY; CYSTIC FIBROSIS; CYSTIC FIBROSIS LUNG DISEASE; EPITHELIAL LINING FLUID; HUMAN; HYPOXIA; INTRACELLULAR SIGNALING; LUNG ALVEOLUS MACROPHAGE; LUNG DISEASE; LUNG FIBROSIS; LUNG FUNCTION; MUCOCILIARY CLEARANCE; MUCOSAL IMMUNITY; NEUTROPHIL; NONHUMAN; PNEUMONIA; RESPIRATORY TRACT INFLAMMATION; REVIEW; TREATMENT DURATION; COMPLICATION; PATHOLOGY;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; CYSTIC FIBROSIS; HUMANS; PNEUMONIA;

EID: 84937631483     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2015.03.003     Document Type: Review

References (151)

1. Meyerholz D.K., Stoltz D.A., Namati E., Ramachandran S., Pezzulo A.A., Smith A.R., et al. Loss of cystic fibrosis transmembrane conductance regulator function produces abnormalities in tracheal development in neonatal pigs and young children. Am J Respir Crit Care Med 2010, 182:1251-1261.
2. Stoltz D.A., Meyerholz D.K., Pezzulo A.A., Ramachandran S., Rogan M.P., Davis G.J., et al. Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth. Sci Transl Med 2010, 2(29):ra31.
3. Muhlebach M.S., Stewart P.W., Leigh M.W., Noah T.L. Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients. Am J Respir Crit Care Med 1999, 160:186-191.
4. Sly P.D., Gangell C.L., Chen L., Ware R.S., Ranganathan S., Mott L.S., et al. Risk factors for bronchiectasis in children with cystic fibrosis. N Engl J Med 2013, 368:1963-1970.
5. Tiringer K., Treis A., Fucik P., Gona M., Gruber S., Renner S., et al. A Th17- and Th2-skewed cytokine profile in cystic fibrosis lungs represents a potential risk factor for Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2013, 187:621-629.
6. Lloyd-Still J.D. Crohn's disease and cystic fibrosis. Dig Dis Sci 1994, 39:880-885.
7. Riordan J.R., Rommens J.M., Kerem B., Alon N., Rozmahel R., Grzelczak Z., et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA [published erratum appears in Science 1989 Sep 29;245(4925):1437]. Science 1989, 245:1066-1073.
8. Pezzulo A.A., Tang X.X., Hoegger M.J., Alaiwa M.H., Ramachandran S., Moninger T.O., et al. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature 2012, 487:109-113.
9. Hoegger M.J., Fischer A.J., McMenimen J.D., Ostedgaard L.S., Tucker A.J., Awadalla M.A., et al. Cystic fibrosis impaired mucus detachment disrupts mucociliary transport in a piglet model of cystic fibrosis. Science 2014, 345:818-822.
10. Boucher R.C. An overview of the pathogenesis of cystic fibrosis lung disease. Adv Drug Deliv Rev 2002, 54:1359-1371.
11. Boucher R.C. Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. Annu Rev Med 2007, 58:157-170.
12. Perez-Vilar J., Boucher R.C. Reevaluating gel-forming mucins' roles in cystic fibrosis lung disease. Free Radic Biol Med 2004, 37:1564-1577.
13. Collawn J.F., Matalon S. CFTR and lung homeostasis. Am J Physiol Lung Cell Mol Physiol 2014, 00326:02014. (ajplung).
14. Button B., Cai L.H., Ehre C., Kesimer M., Hill D.B., Sheehan J.K., et al. A periciliary brush promotes the lung health by separating the mucus layer from airway epithelia. Science 2012, 337:937-941.
15. Cantin A.M., Hanrahan J.W., Bilodeau G., Ellis L., Dupuis A., Liao J., et al. Cystic fibrosis transmembrane conductance regulator function is suppressed in cigarette smokers. Am J Respir Crit Care Med 2006, 173:1139-1144.
16. Swiatecka-Urban A., Moreau-Marquis S., Maceachran D.P., Connolly J.P., Stanton C.R., Su J.R., et al. Pseudomonas aeruginosa inhibits endocytic recycling of CFTR in polarized human airway epithelial cells. Am J Physiol Cell Physiol 2006, 290:C862-C872.
17. Worlitzsch D., Tarran R., Ulrich M., Schwab U., Cekici A., Meyer K.C., et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 2002, 109:317-325.
18. Scortegagna M., Cataisson C., Martin R.J., Hicklin D.J., Schreiber R.D., Yuspa S.H., et al. HIF-1alpha regulates epithelial inflammation by cell autonomous NFkappaB activation and paracrine stromal remodeling. Blood 2008, 111:3343-3354.
19. Legendre C., Mooij M.J., Adams C., O'Gara F. Impaired expression of hypoxia-inducible factor-1alpha in cystic fibrosis airway epithelial cells - a role for HIF-1 in the pathophysiology of CF?. J Cyst Fibros 2011, 10:286-290.
20. Song Y., Salinas D., Nielson D.W., Verkman A.S. Hyperacidity of secreted fluid from submucosal glands in early cystic fibrosis. Am J Physiol Cell Physiol 2006, 290:C741-C749.
21. Welsh M.J., Smith J.J. cAMP stimulation of HCO3-secretion across airway epithelia. JOP 2001, 2:291-293.
22. Coakley R.D., Grubb B.R., Paradiso A.M., Gatzy J.T., Johnson L.G., Kreda S.M., et al. Abnormal surface liquid pH regulation by cultured cystic fibrosis bronchial epithelium. Proc Natl Acad Sci U S A 2003, 100:16083-16088.
23. Shamsuddin A.K., Quinton P.M. Native small airways secrete bicarbonate. Am J Respir Cell Mol Biol 2014, 50:796-804.
24. Poulsen J.H., Fischer H., Illek B., Machen T.E. Bicarbonate conductance and pH regulatory capability of cystic fibrosis transmembrane conductance regulator. Proc Natl Acad Sci U S A 1994, 91:5340-5344.
25. -for mucin release. J Clin Invest 2009, 119:2535-2537.
26. Garcia M.A., Yang N., Quinton P.M. Normal mouse intestinal mucus release requires cystic fibrosis transmembrane regulator-dependent bicarbonate secretion. J Clin Invest 2009, 119:2613-2622.
27. Gustafsson J.K., Ermund A., Ambort D., Johansson M.E., Nilsson H.E., Thorell K., et al. Bicarbonate and functional CFTR channel are required for proper mucin secretion and link cystic fibrosis with its mucus phenotype. J Exp Med 2012, 209:1263-1272.
28. Becker K.A., Riethmuller J., Zhang Y., Gulbins E. The role of sphingolipids and ceramide in pulmonary inflammation in cystic fibrosis. Open Respir Med J 2010, 4:39-47.
29. Grassme H., Jendrossek V., Riehle A., von Kurthy G., Berger J., Schwarz H., et al. Host defense against Pseudomonas aeruginosa requires ceramide-rich membrane rafts. Nat Med 2003, 9:322-330.
30. Nahrlich L., Mainz J.G., Adams C., Engel C., Herrmann G., Icheva V., et al. Therapy of CF-patients with amitriptyline and placebo-a randomised, double-blind, placebo-controlled phase IIb multicenter, cohort-study. Cell Physiol Biochem 2013, 31:505-512.
31. Guilbault C., Wojewodka G., Saeed Z., Hajduch M., Matouk E., De Sanctis J.B., et al. Cystic fibrosis fatty acid imbalance is linked to ceramide deficiency and corrected by fenretinide. Am J Respir Cell Mol Biol 2009, 41:100-106.
32. Guilbault C., De Sanctis J.B., Wojewodka G., Saeed Z., Lachance C., Skinner T.A., et al. Fenretinide corrects newly found ceramide deficiency in cystic fibrosis. Am J Respir Cell Mol Biol 2008, 38:47-56.
33. Wojewodka G., De Sanctis J.B., Radzioch D. Ceramide in cystic fibrosis: a potential new target for therapeutic intervention. J Lipids 2011, 2011:674968.
34. Teichgraber V., Ulrich M., Endlich N., Riethmuller J., Wilker B., De Oliveira-Munding C.C., et al. Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat Med 2008, 14:382-391.
35. Freedman S.D., Blanco P.G., Zaman M.M., Shea J.C., Ollero M., Hopper I.K., et al. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med 2004, 350:560-569.
36. Hong S., Gronert K., Devchand P.R., Moussignac R.L., Serhan C.N. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells autacoids in anti-inflammation. J Biol Chem 2003, 278:14677-14687.
37. Morin C., Fortin S., Cantin A.M., Rousseau E. Docosahexaenoic acid derivative prevents inflammation and hyperreactivity in lung: implication of PKC-potentiated inhibitory protein for heterotrimeric myosin light chain phosphatase of 17kD in asthma. Am J Respir Cell Mol Biol 2011, 45:366-375.
38. Yonker L.M., Cigana C., Hurley B.P., Bragonzi A. Host-pathogen interplay in the respiratory environment of cystic fibrosis. J Cyst Fibros 2015, 14:432-440.
39. Kelley T.J., Drumm M.L. Inducible nitric oxide synthase expression is reduced in cystic fibrosis murine and human airway epithelial cells. J Clin Invest 1998, 102:1200-1207.
40. Kreiselmeier N.E., Kraynack N.C., Corey D.A., Kelley T.J. Statin-mediated correction of STAT1 signaling and inducible nitric oxide synthase expression in cystic fibrosis epithelial cells. Am J Physiol Lung Cell Mol Physiol 2003, 285:L1286-L1295.
41. Kushwah R., Gagnon S., Sweezey N.B. Intrinsic predisposition of naive cystic fibrosis T cells to differentiate towards a Th17 phenotype. Respir Res 2013, 14:138.
42. Vandivier R.W., Richens T.R., Horstmann S.A., deCathelineau A.M., Ghosh M., Reynolds S.D., et al. Dysfunctional cystic fibrosis transmembrane conductance regulator inhibits phagocytosis of apoptotic cells with proinflammatory consequences. Am J Physiol Lung Cell Mol Physiol 2009, 297:L677-L686.
43. Ziady A.G., Hansen J. Redox balance in cystic fibrosis. Int J Biochem Cell Biol 2014, 52C:113-123.
44. Blohmke C.J., Mayer M.L., Tang A.C., Hirschfeld A.F., Fjell C.D., Sze M.A., et al. Atypical activation of the unfolded protein response in cystic fibrosis airway cells contributes to p38 MAPK-mediated innate immune responses. J Immunol 2012, 189:5467-5475.
45. Blohmke C.J., Victor R.E., Hirschfeld A.F., Elias I.M., Hancock D.G., Lane C.R., et al. Innate immunity mediated by TLR5 as a novel antiinflammatory target for cystic fibrosis lung disease. J Immunol 2008, 180:7764-7773.
46. Berube J., Roussel L., Nattagh L., Rousseau S. Loss of cystic fibrosis transmembrane conductance regulator function enhances activation of p38 and ERK MAPKs, increasing interleukin-6 synthesis in airway epithelial cells exposed to Pseudomonas aeruginosa. J Biol Chem 2010, 285:22299-22307.
47. Roum J.H., Buhl R., McElvaney N.G., Borok Z., Crystal R.G. Systemic deficiency of glutathione in cystic fibrosis. J Appl Physiol 1993, 75:2419-2424.
48. Velsor L.W., van Heeckeren A., Day B.J. Antioxidant imbalance in the lungs of cystic fibrosis transmembrane conductance regulator protein mutant mice. Am J Physiol Lung Cell Mol Physiol 2001, 281:L31-L38.
49. Linsdell P., Hanrahan J.W. Glutathione permeability of CFTR. Am J Physiol 1998, 275:C323-C326.
50. Cantin A.M., Paquette B., Richter M., Larivee P. Albumin-mediated regulation of cellular glutathione and nuclear factor kappa B activation. Am J Respir Crit Care Med 2000, 162:1539-1546.
51. Painter R.G., Marrero L., Lombard G.A., Valentine V.G., Nauseef W.M., Wang G. CFTR-mediated halide transport in phagosomes of human neutrophils. J Leukoc Biol 2010, 87:933-942.
52. Lamothe J., Valvano M.A. Burkholderia cenocepacia-induced delay of acidification and phagolysosomal fusion in cystic fibrosis transmembrane conductance regulator (CFTR)-defective macrophages. Microbiology 2008, 154:3825-3834.
53. Zhang P.X., Murray T.S., Villella V.R., Ferrari E., Esposito S., D'Souza A., et al. Reduced caveolin-1 promotes hyperinflammation due to abnormal heme oxygenase-1 localization in lipopolysaccharide-challenged macrophages with dysfunctional cystic fibrosis transmembrane conductance regulator. J Immunol 2013, 190:5196-5206.
54. Mall M.A., Hartl D. CFTR: cystic fibrosis and beyond. Eur Respir J 2014, 44:1042-1054.
55. Nauseef W.M., Borregaard N. Neutrophils at work. Nat Immunol 2014, 15:602-611.
56. Cantin A.M., Bilodeau G., Ouellet C., Liao J., Hanrahan J.W. Oxidant stress suppresses CFTR expression. Am J Physiol Cell Physiol 2006, 290:C262-C270.
57. Le Gars M., Descamps D., Roussel D., Saussereau E., Guillot L., Ruffin M., et al. Neutrophil elastase degrades cystic fibrosis transmembrane conductance regulator via calpains and disables channel function in vitro and in vivo. Am J Respir Crit Care Med 2013, 187:170-179.
58. Hartl D., Gaggar A., Bruscia E., Hector A., Marcos V., Jung A., et al. Innate immunity in cystic fibrosis lung disease. J Cyst Fibros 2012, 11:363-382.
59. Greene C.M., McElvaney N.G. Proteases and antiproteases in chronic neutrophilic lung disease - relevance to drug discovery. Br J Pharmacol 2009, 158:1048-1058.
60. Hartl D., Latzin P., Hordijk P., Marcos V., Rudolph C., Woischnik M., et al. Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease. Nat Med 2007, 13:1423-1430.
61. Perera N.C., Schilling O., Kittel H., Back W., Kremmer E., Jenne D.E. NSP4, an elastase-related protease in human neutrophils with arginine specificity. Proc Natl Acad Sci U S A 2012, 109:6229-6234.
62. Korkmaz B., Horwitz M.S., Jenne D.E., Gauthier F. Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases. Pharmacol Rev 2010, 62:726-759.
63. Hirche T.O., Benabid R., Deslee G., Gangloff S., Achilefu S., Guenounou M., et al. Neutrophil elastase mediates innate host protection against Pseudomonas aeruginosa. J Immunol 2008, 181:4945-4954.
64. Sedor J., Hogue L., Akers K., Boslaugh S., Schreiber J., Ferkol T. Cathepsin-G interferes with clearance of Pseudomonas aeruginosa from mouse lungs. Pediatr Res 2007, 61:26-31.
65. Gehrig S., Duerr J., Weitnauer M., Wagner C.J., Graeber S.Y., Schatterny J., et al. Lack of neutrophil elastase reduces inflammation, mucus hypersecretion, and emphysema, but not mucus obstruction, in mice with cystic fibrosis-like lung disease. Am J Respir Crit Care Med 2014, 189:1082-1092.
66. Bruce M.C., Poncz L., Klinger J.D., Stern R.C., Tomashefski J.F., Dearborn D.G. Biochemical and pathologic evidence for proteolytic destruction of lung connective tissue in cystic fibrosis. Am Rev Respir Dis 1985, 132:529-535.
67. Sommerhoff C.P., Nadel J.A., Basbaum C.B., Caughey G.H. Neutrophil elastase and cathepsin G stimulate secretion from cultured bovine airway gland serous cells. J Clin Invest 1990, 85:682-689.
68. Voynow J.A., Young L.R., Wang Y., Horger T., Rose M.C., Fischer B.M. Neutrophil elastase increases MUC5AC mRNA and protein expression in respiratory epithelial cells. Am J Physiol 1999, 276:L835-L843.
69. Berger M., Sorensen R.U., Tosi M.F., Dearborn D.G., Doring G. Complement receptor expression on neutrophils at an inflammatory site, the Pseudomonas-infected lung in cystic fibrosis. J Clin Invest 1989, 84:1302-1313.
70. Tosi M.F., Zakem H., Berger M. Neutrophil elastase cleaves C3bi on opsonized pseudomonas as well as CR1 on neutrophils to create a functionally important opsonin receptor mismatch. J Clin Invest 1990, 86:300-308.
71. Vandivier R.W., Fadok V.A., Hoffmann P.R., Bratton D.L., Penvari C., Brown K.K., et al. Elastase-mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystic fibrosis and bronchiectasis. J Clin Invest 2002, 109:661-670.
72. Vandivier R.W., Fadok V.A., Ogden C.A., Hoffmann P.R., Brain J.D., Accurso F.J., et al. Impaired clearance of apoptotic cells from cystic fibrosis airways. Chest 2002, 121:89S.
73. Vega-Carrascal I., Bergin D.A., McElvaney O.J., McCarthy C., Banville N., Pohl K., et al. Galectin-9 signaling through TIM-3 is involved in neutrophil-mediated Gram-negative bacterial killing: an effect abrogated within the cystic fibrosis lung. J Immunol 2014, 192:2418-2431.
74. Gaggar A., Hector A., Bratcher P.E., Mall M.A., Griese M., Hartl D. The role of matrix metalloproteinases in cystic fibrosis lung disease. Eur Respir J 2011, 38:721-727.
75. Trojanek J.B., Cobos-Correa A., Diemer S., Kormann M., Schubert S.C., Zhou-Suckow Z., et al. Airway mucus obstruction triggers macrophage activation and matrix metalloproteinase 12-dependent emphysema. Am J Respir Cell Mol Biol 2014, 51:709-720.
76. Sagel S.D., Kapsner R.K., Osberg I. Induced sputum matrix metalloproteinase-9 correlates with lung function and airway inflammation in children with cystic fibrosis. Pediatr Pulmonol 2005, 39:224-232.
77. Cosgrove S., Chotirmall S.H., Greene C.M., McElvaney N.G. Pulmonary proteases in the cystic fibrosis lung induce interleukin 8 expression from bronchial epithelial cells via a heme/meprin/epidermal growth factor receptor/toll-like receptor pathway. J Biol Chem 2011, 286:7692-7704.
78. Gaggar A., Jackson P.L., Noerager B.D., O'Reilly P.J., McQuaid D.B., Rowe S.M., et al. A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation. J Immunol 2008, 180:5662-5669.
79. Weldon S., McNally P., McAuley D.F., Oglesby I.K., Wohlford-Lenane C.L., Bartlett J.A., et al. miR-31 dysregulation in cystic fibrosis airways contributes to increased pulmonary cathepsin S production. Am J Respir Crit Care Med 2014, 190:165-174.
80. Griese M., Kappler M., Gaggar A., Hartl D. Inhibition of airway proteases in cystic fibrosis lung disease. Eur Respir J 2008, 32:783-795.
81. Lorenz E., Muhlebach M.S., Tessier P.A., Alexis N.E., Duncan Hite R., Seeds M.C., et al. Different expression ratio of S100A8/A9 and S100A12 in acute and chronic lung diseases. Respir Med 2008, 102:567-573.
82. Kang J.H., Hwang S.M., Chung I.Y. S100A8, S100A9 and S100A12 activate airway epithelial cells to produce MUC5AC via extracellular signal-regulated kinase and nuclear factor-kappaB pathways. Immunology 2015, 144:79-90.
83. Hartl D., Griese M., Kappler M., Zissel G., Reinhardt D., Rebhan C., et al. Pulmonary T(H)2 response in Pseudomonas aeruginosa-infected patients with cystic fibrosis. J Allergy Clin Immunol 2006, 117:204-211.
84. Iannitti R.G., Carvalho A., Cunha C., De Luca A., Giovannini G., Casagrande A., et al. Th17/Treg imbalance in murine cystic fibrosis is linked to indoleamine 2,3-dioxygenase deficiency but corrected by kynurenines. Am J Respir Crit Care Med 2013, 187:609-620.
85. Moss R.B., Hsu Y.P., Olds L. Cytokine dysregulation in activated cystic fibrosis (CF) peripheral lymphocytes. Clin Exp Immunol 2000, 120:518-525.
86. Rieber N., Brand A., Hector A., Graepler-Mainka U., Ost M., Schafer I., et al. Flagellin induces myeloid-derived suppressor cells: implications for Pseudomonas aeruginosa infection in cystic fibrosis lung disease. J Immunol 2013, 190:1276-1284.
87. Anil N., Singh M. CD4(+)CD25(high) FOXP3(+) regulatory T cells correlate with FEV1 in North Indian children with cystic fibrosis. Immunol Invest 2014, 43:535-543.
88. Nichols D., Chmiel J., Berger M. Chronic inflammation in the cystic fibrosis lung: alterations in inter- and intracellular signaling. Clin Rev Allergy Immunol 2008, 34:146-162.
89. Rowe S.M., Heltshe S.L., Gonska T., Donaldson S.H., Borowitz D., Gelfond D., et al. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. Am J Respir Crit Care Med 2014, 190:175-184.
90. Paul K., Rietschel E., Ballmann M., Griese M., Worlitzsch D., Shute J., et al. Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. Am J Respir Crit Care Med 2004, 169:719-725.
91. Ratjen F., Saiman L., Mayer-Hamblett N., Lands L.C., Kloster M., Thompson V., et al. Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa. Chest 2012, 142:1259-1266.
92. Konstan M.W., Byard P.J., Hoppel C.L., Davis P.B. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995, 332:848-854.
93. Konstan M.W., Wagener J.S., Pasta D.J., Millar S.J., Jacobs J.R., Yegin A., et al. Clinical use of dornase alpha is associated with a slower rate of FEV1 decline in cystic fibrosis. Pediatr Pulmonol 2011, 46:545-553.
94. VanDevanter D.R., Sawicki G.S., Foreman A., Pasta D.J., Morgan W.J., Konstan M.W. High dose ibuprofen significantly improves long-term CF survival. Pediatr Pulmonol 2012, 47:354.
95. Mogayzel P.J., Naureckas E.T., Robinson K.A., Mueller G., Hadjiliadis D., Hoag J.B., et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2013, 187:680-689.
96. Auerbach H.S., Williams M., Kirkpatrick J.A., Colten H.R. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet 1985, 2:686-688.
97. Eigen H., Rosenstein B.J., FitzSimmons S., Schidlow D.V. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis Cystic Fibrosis Foundation Prednisone Trial Group. J Pediatr 1995, 126:515-523.
98. Lai H.C., FitzSimmons S.C., Allen D.B., Kosorok M.R., Rosenstein B.J., Campbell P.W., et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. N Engl J Med 2000, 342:851-859.
99. Ren C.L., Pasta D.J., Rasouliyan L., Wagener J.S., Konstan M.W., Morgan W.J., Scientific Advisory, G., The, I., and Coordinators of the Epidemiologic Study of Cystic, F Relationship between inhaled corticosteroid therapy and rate of lung function decline in children with cystic fibrosis. J Pediatr 2008, 153:746-751.
100. Ross K.R., Chmiel J.F., Konstan M.W. The role of inhaled corticosteroids in the management of cystic fibrosis. Paediatr Drugs 2009, 11:101-113.
101. Balfour-Lynn I.M., Lees B., Hall P., Phillips G., Khan M., Flather M., et al. Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis. Am J Respir Crit Care Med 2006, 173:1356-1362.
102. Lands L.C., Milner R., Cantin A.M., Manson D., Corey M. High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. J Pediatr 2007, 151:249-254.
103. Konstan M.W., Schluchter M.D., Xue W., Davis P.B. Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. Am J Respir Crit Care Med 2007, 176:1084-1089.
104. Konstan M.W. Ibuprofen therapy for cystic fibrosis lung disease: revisited. Curr Opin Pulm Med 2008, 14:567-573.
105. Lands L.C., Stanojevic S. Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis. Cochrane Database Syst Rev 2013, 6:CD001505.
106. Ordonez C.L., Henig N.R., Mayer-Hamblett N., Accurso F.J., Burns J.L., Chmiel J.F., et al. Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis. Am J Respir Crit Care Med 2003, 168:1471-1475.
107. Ramsey B.W., Dorkin H.L., Eisenberg J.D., Gibson R.L., Harwood I.R., Kravitz R.M., et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993, 328:1740-1746.
108. Noah T.L., Ivins S.S., Abode K.A., Stewart P.W., Michelson P.H., Harris W.T., et al. Inhaled versus systemic antibiotics and airway inflammation in children with cystic fibrosis and Pseudomonas. Pediatr Pulmonol 2010, 45:281-290.
109. Saiman L., Anstead M., Mayer-Hamblett N., Lands L.C., Kloster M., Hocevar-Trnka J., et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2010, 303:1707-1715.
110. Saiman L., Mayer-Hamblett N., Anstead M., Lands L.C., Kloster M., Goss C.H., et al. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatr Pulmonol 2012, 47:641-648.
111. Milla C.E., Chmiel J.F., Accurso F.J., VanDevanter D.R., Konstan M.W., Yarranton G., Geller D.E., Group K.B.S. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatr Pulmonol 2014, 49:650-658.
112. Chmiel J.F., Konstan M.W., Saadane A., Krenicky J.E., Lester Kirchner H., Berger M. Prolonged inflammatory response to acute Pseudomonas challenge in interleukin-10 knockout mice. Am J Respir Crit Care Med 2002, 165:1176-1181.
113. Chmiel J.F., Konstan M.W., Knesebeck J.E., Hilliard J.B., Bonfield T.L., Dawson D.V., et al. IL-10 attenuates excessive inflammation in chronic Pseudomonas infection in mice. Am J Respir Crit Care Med 1999, 160:2040-2047.
114. Perez A., van Heeckeren A.M., Nichols D., Gupta S., Eastman J.F., Davis P.B. Peroxisome proliferator-activated receptor-gamma in cystic fibrosis lung epithelium. Am J Physiol Lung Cell Mol Physiol 2008, 295:L303-L313.
115. Ollero M., Junaidi O., Zaman M.M., Tzameli I., Ferrando A.A., Andersson C., et al. Decreased expression of peroxisome proliferator activated receptor gamma in cftr-/-mice. J Cell Physiol 2004, 200:235-244.
116. Konstan M., Krenicky J., Hiliard K., Hilliard J. A pilot study evaluating the effect of pioglitazone, simvastatin, and ibuprofen on neutrophil migration in vivo in healthy subjects. Pediatr Pulmonol 2009, 42:289-290.
117. Kelley T.J., Elmer H.L. In vivo alterations of IFN regulatory factor-1 and PIAS1 protein levels in cystic fibrosis epithelium. J Clin Invest 2000, 106:403-410.
118. Meng Q.H., Springall D.R., Bishop A.E., Morgan K., Evans T.J., Habib S., et al. Lack of inducible nitric oxide synthase in bronchial epithelium: a possible mechanism of susceptibility to infection in cystic fibrosis. J Pathol 1998, 184:323-331.
119. Steagall W.K., Elmer H.L., Brady K.G., Kelley T.J. Cystic fibrosis transmembrane conductance regulator-dependent regulation of epithelial inducible nitric oxide synthase expression. Am J Respir Cell Mol Biol 2000, 22:45-50.
120. Moss R.B., Mayer-Hamblett N., Wagener J., Daines C., Hale K., Ahrens R., et al. Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease. Pediatr Pulmonol 2005, 39:209-218.
121. Kraynack N.C., Corey D.A., Elmer H.L., Kelley T.J. Mechanisms of NOS2 regulation by Rho GTPase signaling in airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 2002, 283:L604-L611.
122. Kraynack N.C., Chmiel J., Xue W., Schluchter M.D., Gibson R.L., Kelley T.J., et al. Effect of simvastatin on exhaled nitric oxide and inflammatory markers in sputum in patients with cystic fibrosis. Pediatr Pulmonol 2008, 43:S300.
123. Grasemann H., Schwiertz R., Matthiesen S., Racke K., Ratjen F. Increased arginase activity in cystic fibrosis airways. Am J Respir Crit Care Med 2005, 172:1523-1528.
124. Grasemann H., Grasemann C., Kurtz F., Tietze-Schillings G., Vester U., Ratjen F. Oral l-arginine supplementation in cystic fibrosis patients: a placebo-controlled study. Eur Respir J 2005, 25:62-68.
125. 2 and inflammatory cytokine production. PLoS One 2008, 3:e3367.
126. Nichols D.P., Ziady A.G., Shank S.L., Eastman J.F., Davis P.B. The triterpenoid CDDO limits inflammation in preclinical models of cystic fibrosis lung disease. Am J Physiol Lung Cell Mol Physiol 2009, 297:L828-L836.
127. Moss R.B., Mistry S.J., Konstan M.W., Pilewski J.M., Kerem E., Tal-Singer R., et al. Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis. J Cyst Fibros 2013, 12:241-248.
128. McAllister F., Henry A., Kreindler J.L., Dubin P.J., Ulrich L., Steele C., et al. Role of IL-17A, IL-17F, and the IL-17 receptor in regulating growth-related oncogene-alpha and granulocyte colony-stimulating factor in bronchial epithelium: implications for airway inflammation in cystic fibrosis. J Immunol 2005, 175:404-412.
129. Konstan M.W., Walenga R.W., Hilliard K.A., Hilliard J.B. Leukotriene B4 markedly elevated in the epithelial lining fluid of patients with cystic fibrosis. Am Rev Respir Dis 1993, 148:896-901.
130. Konstan M.W., Doring G., Heltshe S.L., Lands L.C., Hilliard K.A., Koker P., et al. A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis. J Cyst Fibros 2014, 13:148-155.
131. Doring G., Bragonzi A., Paroni M., Akturk F.F., Cigana C., Schmidt A., et al. BIIL 284 reduces neutrophil numbers but increases P. aeruginosa bacteremia and inflammation in mouse lungs. J Cyst Fibros 2014, 13:156-163.
132. Griese M., Latzin P., Kappler M., Weckerle K., Heinzlmaier T., Bernhardt T., et al. alpha1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. Eur Respir J 2007, 29:240-250.
133. Cantin A.M. Potential for antioxidant therapy of cystic fibrosis. Curr Opin Pulm Med 2004, 10:531-536.
134. Ouellet C., Bilodeau G., Cantin A.M. Oxidative stress, smoking and CFTR: can cystic fibrosis be acquired?. Med Sci (Paris) 2007, 23:9-10.
135. Roum J.H., Buhl R., McElvaney N.G., Borok Z., Crystal R.G. 1993. Systemic deficiency of glutathione in cystic fibrosis. J Appl Physiol 1985, 75:2419-2424.
136. Bishop C., Hudson V.M., Hilton S.C., Wilde C. A pilot study of the effect of inhaled buffered reduced glutathione on the clinical status of patients with cystic fibrosis. Chest 2005, 127:308-317.
137. Hartl D., Starosta V., Maier K., Beck-Speier I., Rebhan C., Becker B.F., et al. Inhaled glutathione decreases PGE2 and increases lymphocytes in cystic fibrosis lungs. Free Radic Biol Med 2005, 39:463-472.
138. Griese M., Kappler M., Eismann C., Ballmann M., Junge S., Rietschel E., et al. Inhalation treatment with glutathione in patients with cystic fibrosis. A randomized clinical trial. Am J Respir Crit Care Med 2013, 188:83-89.
139. Tirouvanziam R., Conrad C.K., Bottiglieri T., Herzenberg L.A., Moss R.B., Herzenberg L.A. High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc Natl Acad Sci U S A 2006, 103:4628-4633.
140. Conrad C., Lymp J., Thompson V., Dunn C., Davies Z., Chatfield B., et al. Long-term treatment with oral N-acetylcysteine: affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial. J Cyst Fibros 2015, 14:219-227.
141. Aldamiz-Echevarria L., Prieto J.A., Andrade F., Elorz J., Sojo A., Lage S., et al. Persistence of essential fatty acid deficiency in cystic fibrosis despite nutritional therapy. Pediatr Res 2009, 66:585-589.
142. Van Biervliet S., Devos M., Delhaye T., Van Biervliet J.P., Robberecht E., Christophe A. Oral DHA supplementation in DeltaF508 homozygous cystic fibrosis patients. Prostaglandins Leukot Essent Fatty Acids 2008, 78:109-115.
143. Karp C.L., Flick L.M., Park K.W., Softic S., Greer T.M., Keledjian R., et al. Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat Immunol 2004, 5:388-392.
144. Mueller C., Braag S.A., Martino A.T., Tang Q., Campbell-Thompson M., Flotte T.R. The pros and cons of immunomodulatory IL-10 gene therapy with recombinant AAV in a CFTR-/--dependent allergy mouse model. Gene Ther 2009, 16:172-183.
145. Saadane A., Masters S., DiDonato J., Li J., Berger M. Parthenolide inhibits IkappaB kinase, NF-kappaB activation, and inflammatory response in cystic fibrosis cells and mice. Am J Respir Cell Mol Biol 2007, 36:728-736.
146. Mackerness K.J., Jenkins G.R., Bush A., Jose P.J. Characterisation of the range of neutrophil stimulating mediators in cystic fibrosis sputum. Thorax 2008, 63:614-620.
147. Cantin A.M., White T.B., Cross C.E., Forman H.J., Sokol R.J., Borowitz D. Antioxidants in cystic fibrosis. Conclusions from the CF antioxidant workshop, Bethesda, Maryland, November 11-12, 2003. Free Radic Biol Med 2007, 42:15-31.
148. Raghavan K.S., Gray D.B., Scholz T.H., Nemeth G.A., Hussain M.A. Degradation kinetics of DMP 777, an elastase inhibitor. Pharm Res 1996, 13:1815-1820.
149. Attucci S., Gauthier A., Korkmaz B., Delepine P., Martino M.F., Saudubray F., et al. EPI-hNE4, a proteolysis-resistant inhibitor of human neutrophil elastase and potential anti-inflammatory drug for treating cystic fibrosis. J Pharmacol Exp Ther 2006, 318:803-809.
150. Cooley J., Sontag M.K., Accurso F.J., Remold-O'Donnell E. SerpinB1 in cystic fibrosis airway fluids: quantity, molecular form and mechanism of elastase inhibition. Eur Respir J 2011, 37:1083-1090.
151. McElvaney N.G., Nakamura H., Birrer P., Hebert C.A., Wong W.L., Alphonso M., et al. Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J Clin Invest 1992, 90:1296-1301.